circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway

Gefitinib is a first-line treatment for patients with non-small-cell lung cancer (NSCLC), but acquired resistance is a major obstacle to its therapeutic efficacy, and the underlying mechanisms are not fully elucidated. Recent studies have indicated that circular RNAs play a crucial role in chemoresi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Ther Nucleic Acids
Egile Nagusiak: Huang, Yutang, Dai, Yi, Wen, Chunjie, He, Shuai, Shi, Jingjing, Zhao, Dezhang, Wu, Lanxiang, Zhou, Honghao
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Gene & Cell Therapy 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7452060/
https://ncbi.nlm.nih.gov/pubmed/32805491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtn.2020.07.027
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak